Prosecution Insights
Last updated: November 04, 2026
Application No. 18/006,549

SPRAY DRYING OF SUPERSATURATED SOLUTIONS OF API WITH ACETIC ACID

Final Rejection §103
Filed
Jan 23, 2023
Priority
Jul 24, 2020 — provisional 63/056,094 +7 more
Examiner
KIM, DANIELLE A
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bend Research Inc.
OA Round
4 (Final)
36%
Grant Probability
At Risk
5-6
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allowance Rate
37 granted / 102 resolved
-23.7% vs TC avg
Strong +52% interview lift
Without
With
+52.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
75 currently pending
Career history
187
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
68.4%
+28.4% vs TC avg
§102
6.2%
-33.8% vs TC avg
§112
17.5%
-22.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 102 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application was filed 23 January 2023 and is the national stage entry of PCT/EP2021/070577 filed 22 July 2021. The Applicant claims priority to several foreign applications as well as provisional application 63/056,094 filed 24 July 2020. The effective filing date of the instant application is 24 July 2020. Examiner’s Note The Applicant's arguments and amendments filed 21 September 2026 are acknowledged and have been fully considered. The Examiner has re-weighed all the evidence of record. Rejections not reiterated from previous office actions are hereby withdrawn. The following rejections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. In the Applicant’s response filed 21 September 2026, it is noted that claim 1 has been amended, no claims have been canceled or newly added. Support for the amendment can be found on pg. 11, ln. 3 of the instant specification. No new matter has been added. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Bittorf (US 2009/0247468 A1) in view of Friesen (Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview, Molecular Pharmaceuticals, 2008), as evidenced by engineeringtoolbox.com. Regarding claim 1, Bittorf teaches a method for spray drying a drug, such as a solid dispersion of the drug (entire teaching; para. 7). A drug is mixed with a suitable solvent or combination of solvents (para. 8), such as acetic acid, dichloromethane, (para. 16) and acetone (para. 128) (providing a first solution and mixing a first solution with a second solution if a combination is used). The composition may become supersaturated as a result of the low pH (para. 165). Polymers, such as HPMCAS, may be included (para. 29). The solvents dissolve both the drug/active agent and polymer (dispersion polymer is in the solvents/solutions), which is interpreted as the active agent not in solid form. The solid dispersion is described as physically and chemically stable (para. 105). Regarding the viscosity becoming lower after the addition of solvents, such as acetic acid and acetone, this limitation is interpreted as necessarily and inherently occurring when mixing a higher viscous solvent (acetic acid, 1.155 cP, engineeringtoolbox.com, pg. 1) and a lower viscous solvent (acetone, 0.316 cP, engineeringtoolbox.com, pg. 1). Bittorf teaches adding acetic acid in an amount of 0.1-15% (para. 18) and acetone in an amount of 20-35% (para. 18). Therefore, considering acetic acid has a viscosity that is three times higher than acetone and incorporating acetone in a higher amount than acetic acid, a skilled artisan would have been led to believe that the resulting supersaturated solution would have a lower viscosity than the first solvent. Furthermore, the amounts of solvent to be added that would result in a lower viscosity supersaturated solution can be viewed as a variable that achieves the recognized result of successfully making the supersaturated composition and improving the properties of the product that is a result of varying the solvents and presumably the amounts of solvents (para. 7), which a skilled artisan would have been easily motivated to modify and adjust based on the broad teachings of Bittorf. The optimum or workable range of amounts can be accordingly characterized as routine optimization and experimentation (see MPEP 2144.05 (II)B). “[Discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” In re Boesch, 617 F.2d 272, 276 (CCPA 1980). Applicants provide no evidence of any secondary consideration, such as unexpected results, that would render the optimized amounts of solvents as nonobvious. Regarding claim 2, the composition comprises polymers, such as HPMCAS (para. 29). Regarding claim 3, the composition comprises polymers, such as HPMCAS (para. 29). Regarding claim 4, the composition comprises polymers, such as HPMCAS (para. 29). Regarding claim 5, a drug is mixed with a suitable solvent or combination of solvents (para. 8), such as acetic acid, dichloromethane, (para. 16) and acetone (para. 128). Regarding claim 6, a drug is mixed with a suitable solvent or combination of solvents (para. 8), such as acetic acid, dichloromethane, (para. 16) and acetone (para. 128). Regarding claim 7, a drug is mixed with a suitable solvent or combination of solvents (para. 8), such as acetic acid, dichloromethane, (para. 16) and acetone (para. 128). Regarding claim 8, Bittorf teaches examples where the solvent may comprise 40-80% of dichloromethane or 25-30% of acetone, or 3-12% of acetic acid (para. 18 and 135). Bittorf also provides examples of a weight ratio of dichloromethane to acetone to water, such as 75:24:1 (para. 131). Regarding claim 9, Bittorf teaches a method for spray drying a drug, such as a solid dispersion of the drug (entire teaching; para. 7). Regarding claim 10, a drug is mixed with a suitable solvent or combination of solvents (para. 8), such as acetic acid, dichloromethane, (para. 16) and acetone (para. 128). The combination of solvents, such as with a non-volatile solvent like acetic acid and a volatile solvent, such as dichloromethane or acetone (para. 16), are interpreted as first and second solvents. Regarding claim 11, a drug is mixed with a suitable solvent or combination of solvents (para. 8), such as acetic acid, dichloromethane, (para. 16) and acetone (para. 128). The combination of solvents, such as with a non-volatile solvent like acetic acid and a volatile solvent, such as dichloromethane or acetone (para. 16), are interpreted as first and second solvents. Regarding claim 12, the composition comprises polymers, such as HPMCAS (para. 29). Regarding claim 13, the composition comprises polymers, such as HPMCAS (para. 29). Regarding claim 14, Bittorf teaches examples where the solvent may comprise 40-80% of dichloromethane or 25-30% of acetone, or 3-12% of acetic acid (para. 18 and 135). Bittorf also provides examples of a weight ratio of dichloromethane to acetone to water, such as 75:24:1 (para. 131). Regarding claim 15, Bittorf teaches a method for spray drying a drug, such as a solid dispersion of the drug (entire teaching; para. 7). Regarding claim 16, the combination of solvents, such as with a non-volatile solvent like acetic acid and a volatile solvent, such as dichloromethane or acetone (para. 16), are interpreted as first and second solvents. Regarding claim 17, the combination of solvents, such as with a non-volatile solvent like acetic acid and a volatile solvent, such as dichloromethane or acetone (para. 16), are interpreted as first and second solvents. Regarding claim 18, the combination of solvents, such as with a non-volatile solvent like acetic acid and a volatile solvent, such as dichloromethane or acetone (para. 16), are interpreted as first and second solvents. Regarding claim 19, Bittorf teaches examples where the solvent may comprise 40-80% of dichloromethane or 25-30% of acetone, or 3-12% of acetic acid (para. 18 and 135). Bittorf also provides examples of a weight ratio of dichloromethane to acetone to water, such as 75:24:1 (para. 131). Regarding claim 20, Bittorf teaches a method for spray drying a drug, such as a solid dispersion of the drug (entire teaching; para. 7). Regarding claim 21, the viscosity becoming lower after the addition of solvents, such as acetic acid and acetone, is interpreted as necessarily and inherently occurring when mixing a higher viscous solvent (acetic acid, 1.155 cP, engineeringtoolbox.com, pg. 1) and a lower viscous solvent (acetone, 0.316 cP, engineeringtoolbox.com, pg. 1). Bittorf teaches adding acetic acid in an amount of 0.1-15% (para. 18) and acetone in an amount of 20-35% (para. 18). Therefore, considering acetic acid has a viscosity that is three times higher than acetone and incorporating acetone in a higher amount than acetic acid, a skilled artisan would have been led to believe that the resulting supersaturated solution would have a lower viscosity than the first solvent. Furthermore, the amounts of solvents to be added that would result in a lower viscosity supersaturated solution can be viewed as a variable that achieves the recognized result of successfully making the supersaturated composition and improving the properties of the product that is a result of varying the solvents and presumably the amounts of solvents (para. 7), which a skilled artisan would have been easily motivated to modify and adjust based on the broad teachings of Bittorf. The optimum or workable range of amounts can be accordingly characterized as routine optimization and experimentation (see MPEP 2144.05 (II)B). “[Discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” In re Boesch, 617 F.2d 272, 276 (CCPA 1980). Applicants provide no evidence of any secondary consideration, such as unexpected results, that would render the optimized amounts of solvents as nonobvious. Bittorf does not teach Applicant’s elected species of methanol. Friesen teaches that solid dispersions with HPMCAS are very soluble in solvents, such as methanol and provides an economical advantage for the spray drying process (pg. 1009). In regards to selecting the combination of acetic acid and HPMCAS in at least claim 1, “[w]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious.” KSR v. Teleflex, 127 S.Ct. 1727, 1740 (2007) (quoting Sakraida v. A.G.Pro, 425 U.S. 273, 282 (1976)). “When the question is whether a patent claiming the combination of elements of prior art is obvious,” the relevant question is “whether the improvement is more than the predictable use of prior art elements according to their established functions.” (Id.). Addressing the issue of obviousness, the Supreme Court noted that the analysis under 35 USC 103 “need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ.” KSR at 1741. The Court emphasized that “[a] person of ordinary skill is… a person of ordinary creativity, not an automaton.” Id. at 1742. Consistent with this reasoning, it would have been obvious to have selected various combinations of various disclosed ingredients from within a prior art disclosure, to arrive at compositions “yielding no more than one would expect from such an arrangement.” Since Bittorf does not teach methanol as one of their solvents, one of ordinary skill in the art would have been motivated to use methanol from Friesen’s teaching that solid dispersions with HPMCAS are very soluble in methanol with a reasonable expectation of success. A skilled artisan would be able to adjust the solvents of their composition based on the drug of choice and therefore would have been led to use methanol as one of their solvents to increase solubility of their solid dispersion. Generally, it is prima facie obvious to substitute one equivalent component or process for another, each of which is taught by the prior art to be useful for the same purpose (see MPEP 2144.06). In regards to the amount of acetic acid in claim 1 and the ratios in claims 8, 14, and 19, Bittorf teaches examples where the solvent may comprise 40-80% of dichloromethane or 25-30% of acetone, or 3-12% of acetic acid (para. 18 and 135). However, a skilled artisan would be able to adjust and optimize the amounts of solvents based on the properties, characteristics, and solubilities of the drugs in their composition. Bittorf also provides examples of a weight ratio of dichloromethane to acetone to water, such as 75:24:1 (para. 131). That being said and in lieu of objective evidence of unexpected results, the amounts and ratios of solvents can be viewed as a variable that achieves the recognized result of successfully performing the method of making a solid dispersion. The optimum or workable range of dosing can be accordingly characterized as routine optimization and experimentation (see MPEP 2144.05 (II)B). “[Discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” In re Boesch, 617 F.2d 272, 276 (CCPA 1980). Applicants provide no evidence of any secondary consideration such as unexpected results that would render the optimized amounts and ratios of solvents as nonobvious. Response to Arguments Applicant's arguments filed 21 September 2026 have been fully considered but they are not persuasive. The Applicant argues that there is no motivation to optimize the amount of acetic acid (Remarks, pgs. 6-7). Applicant’s argument is not found persuasive. Bittorf teaches a broad range of solvent amounts appropriate for making the supersaturated solution. For example, Bittorf teaches adding acetic acid in an amount of 0.1-15% (para. 18) and acetone in an amount of 20-35% (para. 18) and that varying the solvents, and presumably the amounts of solvents, results in superior properties of the product (para. 7). Bittorf additionally teaches that parameters that can be varied and optimized for the purpose of spray drying, wherein the different parameters include choice of solvent and amounts of solvents used (para. 139). Therefore, a person of ordinary skill in the art would have been motivated to adjust and optimize the parameters and amounts as part of routine experimentation (see MPEP 2144.05 (II)B). “[Discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” In re Boesch, 617 F.2d 272, 276 (CCPA 1980). Applicants provide no evidence of any secondary consideration such as unexpected results that would render the optimized amounts and ratios of solvents as nonobvious. The Applicant argues that Bittorf does not teach a supersaturated feed solution (Remarks, pg. 6). Applicant’s argument is not found persuasive. Bittorf teaches that the composition may become supersaturated as a result of the low pH (para. 165). The mixture to be spray dried may also be in the form of a suspension (claim 2). The dispersion polymers prevent crystallization despite being supersaturated while in its dosage form (para. 165). Furthermore, the method of preparation described in Bittorf is similar to Applicant’s description of a solvent shift that forms a supersaturated solution. A poorly soluble drug is mixed with high viscosity acetic acid and then another low viscosity solvent, such as acetone (instant specification pg. 4), to form a metastable supersaturated solution of API in the solvent mixture (instant specification, pg. 4). Therefore, a person of ordinary skill in the art would be able to reasonably conclude that the mixture in the form of a suspension before spray drying in Bittorf’s teaching is also supersaturated. The Applicant argues that mixing acetic acid with acetone will not necessarily and inherently yield a solution with viscosity at least half that of the first solvent (Remarks, pgs. 7-8). Applicant’s argument is not found persuasive. Regarding the viscosity becoming lower after the addition of solvents, such as acetic acid and acetone, this limitation is interpreted as necessarily and inherently occurring when mixing a higher viscous solvent (acetic acid, 1.155 cP, engineeringtoolbox.com, pg. 1) and a lower viscous solvent (acetone, 0.316 cP, engineeringtoolbox.com, pg. 1). Bittorf teaches adding acetic acid in an amount of 0.1-15% (para. 18) and acetone in an amount of 20-35% (para. 18). Therefore, considering acetic acid has a viscosity that is three times higher than acetone and incorporating acetone in a higher amount than acetic acid, a skilled artisan would have been led to believe that the resulting supersaturated solution would have a lower viscosity than the first solvent. Furthermore, the amounts of solvents to be added that would result in a lower viscosity supersaturated solution can be viewed as a variable that achieves the recognized result of successfully making the supersaturated composition and improving the properties of the product that is a result of varying the solvents and presumably the amounts of solvents (para. 7), which a skilled artisan would have been easily motivated to modify and adjust based on the broad teachings of Bittorf. The optimum or workable range of amounts can be accordingly characterized as routine optimization and experimentation (see MPEP 2144.05 (II)B). “[Discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” In re Boesch, 617 F.2d 272, 276 (CCPA 1980). Applicants provide no evidence of any secondary consideration, such as unexpected results, that would render the optimized amounts of solvents as nonobvious. Additionally, it is noted that the instant specification states that the supersaturated solution preferably has a viscosity that is two to three times lower than the viscosity of the first solution (pg. 15). The first solution includes AA (any drug, small molecule, etc., pg. 10 of instant specification) and acetic acid. The supersaturated solution is a mixture of solvent 1 (acetic acid), solvent 2 (methanol, ethanol, acetone, etc.), and AA (pg. 6 of instant specification). The U.S. Patent Office is not equipped with analytical instruments to test prior art compositions for the infinite number of ways that a subsequent applicant may present previously unmeasured characteristics. When as here, the prior art appears to contain the exact same ingredients and applicant's own disclosure supports the suitability of the prior art composition as the inventive composition component, the burden is properly shifted to applicant to show otherwise. The Applicant refers to Table 2 to show viscosities of polymers (HPMCAS and PVP-VA64) in different solvents (MeOH, MeOH:AcOH, and glacial AcOH). The table is absent of any data regarding the viscosities of the solvents with the drug/active agent. Furthermore, the mixture of MeOH:AcOH results in a lower viscosity than the original mixture with glacial acetic acid. It is noted that the scope of the claimed invention is, broadly, a method comprising any drug, therapeutic agent, API, etc., acetic, acid, and any second solvent (instant claim 1). As such, the data are not commensurate in scope with the claims. “For objective evidence of secondary considerations to be accorded substantial weight, its proponent must establish a nexus between the evidence and the merits of the claimed invention.” Wyers v. Master Lock Co., 616 F.3d 1231, 1246 [95 USPQ2d 1525] (Fed. Cir. 2010) (quotation omitted). Where the offered secondary consideration actually results from something other than what is both claimed and novel in the claim, there is no nexus to the merits of the claimed invention. Tokai Corp. v. Easton Enters., Inc., 632 F.3d 1358, 1369 [97 USPQ2d 1673] (Fed. Cir. 2011) (“If commercial success is due to an element in the prior art, no nexus exists.”); Ormco Corp., 463 F.3d at 1312 (“[I]f the feature that creates the commercial success was known in the prior art, the success is not pertinent.”); In re Woodruff, 919 F.2d 1575, 1578 [16 USPQ2d 1934] (Fed. Cir. 1990). Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danielle Kim whose telephone number is (571)272-2035. The examiner can normally be reached M-F: 9-5 p.m. PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached at (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D.A.K./Examiner, Art Unit 1613 /ANDREW S ROSENTHAL/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Show 2 earlier events
Nov 26, 2025
Response Filed
Jan 21, 2026
Final Rejection mailed — §103
Mar 19, 2026
Response after Non-Final Action
Apr 08, 2026
Request for Continued Examination
Apr 12, 2026
Response after Non-Final Action
Jun 23, 2026
Non-Final Rejection mailed — §103
Sep 21, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778903
PHARMACEUTICAL COMPOSITION AND BREXPIPRAZOLE ORALLY SOLUABLE FILM
2y 10m to grant Granted Nov 03, 2026
Patent 12758485
INSTANT EFFECT EYE CREAM
4y 11m to grant Granted Oct 13, 2026
Patent 12734193
AMMONIUM CHLORIDE FORMULATION TO SUPPORT HUMAN NATURAL DEFENSE AGAINST VIRUSES
4y 9m to grant Granted Sep 15, 2026
Patent 12728081
SUNSCREEN FORMULATION
2y 7m to grant Granted Sep 08, 2026
Patent 12714671
CELL MEMBRANE LIPID-EXTRACTED NANOPARTICLES (CLENS) FOR SELECTIVE TARGETING, IMAGE ANALYSIS AND CANCER THERAPY
5y 7m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
36%
Grant Probability
88%
With Interview (+52.1%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 102 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month